China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk
This article was originally published in The Pink Sheet Daily
Drugs and APIs in four categories now can gain approval in 120 days, down from 150.
You may also be interested in...
AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
James Cai, AstraZeneca's VP, Healthcare Policy Research, sat down with PharmAsia News' Shanghai bureau during the China Trials 2008 conference in November to discuss the burgeoning CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure there.
SHANGHAI - China regulators released a streamlined draft drug approval rule this month that would provide for faster approval of four categories of new drugs. The State Food and Drug Administration finished collecting public comments on the rule Oct. 15
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.